Frilling A, Röher H D, Ponder B A, Goretzki P E, Schlaghecke R, Reiners C
Abteilung für Allgemeine und Unfallchirurgie, Heinrich-Heine-Universität Düsseldorf.
Chirurg. 1993 Jan;64(1):28-35.
Presymptomatic screening of medullary thyroid carcinoma in MEN 2A families enables the early diagnosis of this tumor burdened by significant morbidity. Biochemical screening consists of basal and stimulated serum calcitonin evaluation. Genetic screening is based on DNA analysis using linked DNA markers. Thyroidectomy at an occult tumor stage may provide curative treatment. Calcitonin measurement was carried out in 58 apparently unaffected family members at risk of 11 MEN 2A patients. In 9 individuals calcitonin elevation was detected. All 9 underwent thyroidectomy. Histological examination confirmed medullary thyroid carcinoma in 8 patients and in 1 case C-cell-hyperplasia. Postoperatively 8 patients (89%) are clinically and biochemically tumor-free (mean follow-up 30 months). DNA screening results in one affected family are presented. DNA analysis allowed the recognition of one apparently unaffected individual at risk as MEN 2A gene carrier. One family member at risk was scored as not carrying the gene and may be excluded from further screening.
对患有2A型多发性内分泌腺瘤病(MEN 2A)的家族进行甲状腺髓样癌的症状前筛查,能够实现对这种具有显著发病率的肿瘤的早期诊断。生化筛查包括基础血清降钙素和刺激后血清降钙素评估。基因筛查基于使用连锁DNA标记的DNA分析。在隐匿肿瘤阶段进行甲状腺切除术可能提供治愈性治疗。对11名MEN 2A患者的58名表面上未受影响但有风险的家庭成员进行了降钙素测量。在9名个体中检测到降钙素升高。所有9人均接受了甲状腺切除术。组织学检查证实8例患者患有甲状腺髓样癌,1例为C细胞增生。术后8例患者(89%)在临床和生化方面均无肿瘤(平均随访30个月)。展示了一个受影响家族的DNA筛查结果。DNA分析使得能够识别出一名表面上未受影响但有风险的个体为MEN 2A基因携带者。一名有风险的家族成员被判定不携带该基因,可被排除在进一步筛查之外。